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A B S T R A C T
Purpose: The incidence of polycystic ovary syndrome (PCOS) increases in women with epilepsy (WWE),
which appears to vary with ethnicity. This study was conducted to determine the incidence and risk
factors of PCOS in Chinese WWE.
Methods: The study was carried out in 102 of 139 Chinese WWE at reproductive ages, with 32 receiving
valproic acid (VPA), 40 receiving other antiepileptic drugs (AEDs), and 30 without AEDs therapy. PCOS
was deﬁned as having 2 or more of the following components: polycystic ovaries, hyperandrogenism,
and amenorrhoea or oligomenorrhoea (a/oligomenorrhoea).
Results: One or more isolated components of PCOS were found in 56 (54.9%) patients, with 29 (28.4%)
having polycystic ovaries, 20 (19.6%) with a/oligomenorrhea, 7 (6.9%) with hyperandrogenism, and 13
(12.7%) with deﬁned PCOS. Their average age at the start of seizure was 13.8  6.5 years, younger than
that of patients without these disorders (16.9  8.6 years, p < 0.05). VPA therapy increased the incidence of
PCOS (11/32, 34.4%), in addition to increased blood levels of testosterone and luteinizing hormone (LH) as
well as LH to FSH (follicle-stimulating hormone) ratio. No signiﬁcant relationship was found between the
incidence of PCOS and the type, duration, or frequency of seizures in these WWE.
Conclusion: There is an increased incidence of PCOS in Chinese WWE at reproductive ages, by more than
2 times of that in the general population. Risk factors include seizures starting at a young age and VPA
therapy.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Reproductive endocrine disorders are more common among
women with epilepsy (WWE) than in the general (healthy)
population.1,2 These abnormalities include menstrual disorders
such as oligomenorrhoea or amenorrhoea (a/oligomenorrhoea),
hyperandrogenism, functional hyperprolactinemia, and polycystic
changes in the ovaries or polycystic ovary syndrome (PCOS). These
disorders, particularly PCOS, are associated with infertility,
metabolic disorders, and endometrial carcinoma.3* Corresponding author at: Department of Neurology, First Afﬁliated Hospital of
Sun Yat-Set University, 58 Zhong-Shan Road II, Guangzhou, Guangdong 510080,
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http://dx.doi.org/10.1016/j.seizure.2012.08.001PCOS has been estimated to occur in 4.0–6.8% of women in the
general population. Prevalence of PCOS in WWE has been
previously reported to be from 3.1% to 20%,1 even as high as
(26%).3 These ﬁgures are dependent on multiple factors including
ethnic (racial) differences as well as diagnostic criteria. Prevalence
of PCOS is generally regarded in western WWE to be about 3–4
times of that in the general population.1,3 The etiology of PCOS in
WWE is complex and includes epilepsy itself as well as the
administration of antiepileptic drugs (AEDs). It has been proposed
that epileptic electrical discharges alter secretion of pituitary and
gonadal hormones, thus resulting in reproductive dysfunction.
Studies have demonstrated that PCOS is more common in patients
with partial rather than generalized epilepsy, particularly that of
temporal lobe origin.4–7 On the other hand, it has been shown that
AEDs change circulating levels of reproductive hormones and
contribute to the development of reproductive dysfunction
including PCOS in WWE.1,8,9
Ethnic/racial variation is signiﬁcant in regards to the expression
of PCOS, which takes into account factors such as the prevalence
and severity of obesity, metabolic disorders and their correlates.vier Ltd. All rights reserved.
Table 1
Clinical characteristics of the 102 Chinese WWE evaluated for the study.
Mean age  SD in years 22.0  6.9
Age distribution [n (%)]
<20 years 41 (40.2)
20–29 years 49 (48.0)
30–39 years 10 (9.8)
40 years 2 (2.0)
Mean BMI  SD (kg/m2) 21.9  3.6
Mean age  SD in years at the start of seizure 16.3  8.3
Mean duration of epilepsy  SD in years 6.2  5.5
Type of seizures [n (%)]
SPS, CPS 17 (16.7)
PG, PSG 60 (58.8)
Unclassiﬁable 25 (24.5)
Frequency of seizures [n (%)]
Seizure-free in 3 months 52 (51.0)
Experienced seizures in 3 months 50 (49.0)
Accepting AEDs therapy [n (%)] 72 (70.6%)
Mean age at the start of AEDs  SD in years 17.8  7.04
Mean duration of AEDs therapy  SD in years 2.80  3.3
Type of AEDs
Single drug therapy 49 (68.1)
VPA 21 (29.2)
CBZ 13 (18.1)
LTG 6 (8.3)
TPM 5 (6.9)
OXC 4 (5.6)
Multidrug therapy 23 (31.9)
Notes: SPS, simple partial seizure; CPS, complex partial seizure; PG, primary
generalized seizure; PSG, partial with secondary generalized seizure; VPA, valproic
acid; CBZ, carbamazepine; LTG, lamotrigine; TPM, topiramate; OXC, oxcarbazepine.
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body mass index (BMI) but are more likely to be centrally obese,
and have a milder hyperandrogenic phenotype. In addition, clinical
selection and planning of AED therapy may vary between Asian
and Western WWE. To date, there is a paucity of PCOS studies in
Asian WWE and data regarding PCOS in Chinese WWE, to the best
of our knowledge, is still limited. Thus, we designed this study to
investigate the incidence and risk factors of PCOS in Chinese WWE.
2. Methods
2.1. Subjects
WWE at reproductive ages were recruited at the Department of
Neurology, First Afﬁliated Hospital, Sun Yat-Sen University
(Guangzhou, China). Exclusion criteria include progressive brain
disease, existing diseases in other organs, pregnancy or lactation,
use of psychiatric medicines, oral contraceptives or other
hormonal preparations, and those who had undergone hysterec-
tomy. One hundred and thirty-nine patients matched with the
study design and were enrolled. Among them, 102 patients had
completed the study process. The study was approved by the local
Ethics Committee and informed consent obtained from all patients.
During the study period, patients were kept in contact via
telephone or email and at particular time points, interviewed
face-to-face at the hospital for clinical evaluation, pathological
laboratory investigations and ultrasound examination.
2.2. Clinical examination and medical records
Detailed medical history was obtained from each patient,
including the age of start of seizure, frequency of seizures,
menstrual history, current medication, and other existing diseases.
Epilepsy was diagnosed and the type classiﬁed by the standard of
the International League Against Epilepsy (1981), in which
magnetic resonance imaging (MRI) was regularly performed on
patients except those who were clearly diagnosed with other non-
MRI assessments. Weight, height, and BMI were recorded.
Overweight was deﬁned as having a BMI of 24. Hirsutism was
determined and scored using the Ferryman and Gallwey system,10
with scores 9 as deﬁned hirsutism. Menstrual disorders were
recorded as amenorrhea (absence of a menstrual period),
oligomenorrhea (cycle length longer than 35 days during the last
6 months), and irregular menstrual cycles (cycle length varying
more than 4 days, at least once during the last 6 months).
2.3. B-mode ultrasonography
A transvaginal or transabdominal (in the case with an intact
hymen) B-mode ultrasonography was performed by using a
3.5 MHz transducer to detect ovarian volume, the number and
size of ovarian follicles, and stromal echogenicity during the period
of the ﬁrst 14 days of menstrual cycle. Polycystic ovary was deﬁned
as each ovary existing with 12 or more follicles with size >2 mm in
diameter and/or volume of ovary >10 mL.
2.4. Assessment of circulating hormones
Fasting blood samples were drawn through a forearm vein at
early follicular phase (days 2–5) of the menstrual cycle, centrifuged
immediately to separate the serum, and stored in a 20 8C freezer.
Blood (serum) concentrations of testosterone (T), luteinizing
hormone (LH), follicle-stimulating hormone (FSH), prolactin
(PRL), dehydroepiandrosterone sulfate (DHEAS), estrodial (E2)
and progestogen (P) were measured using chemiluminescent
microparticle immunoassay kits (Abbott Laboratories, USA). Inmeasurements the reference range of T was 0.09–1.3 mg/L, LH
1–18 IU/L, FSH 4–13 IU/L, PRL 1.39–29.93 mg/L, DHEAS 0.2–
13.9 mmol/L, E2 390–1890 pg/L, and P 2.7–26.1 ng/L, with intra-
and inter-assay coefﬁcients with variation less than 8%.
Serum concentration of T > 10.0 mg/L was deﬁned as hyper-
androgenism. In our study, positive clinical symptoms/signs were
usually present when serum levels of T was >10.0 mg/L. Patients
with a single laboratory report of T > 10.0 mg/L but no clinical
symptoms/signs were not included as cases of hyperandrogenism,
in which the hormonal increment was transient and returned back
to normal without particular treatment during the follow-up
period.
2.5. Deﬁnition of PCOS
PCOS was diagnosed based on a coexistence of 2 or more of
these components: polycystic ovaries, hyperandrogenism, and a/
oligomenorrhoea. Although polycystic ovaries are the pathological
basis of PCOS, ultrasonography of a sufﬁcient standard is still not
widely available for the diagnosis of the polycystic ovary.11 In the
case of the absence of the deﬁned polycystic ovary, PCOS would be
deﬁned by an accepted standard for clinical diagnosis of PCOS, i.e.
existence of an ovulatory dysfunction (functional a/oligomenor-
rhoea) with clinical evidence of hyperandrogenism and exclusion
of secondary causes or related disorders such as hyperprolacti-
naemia, thyroid disorders and non classical adrenal hyperplasia.11
2.6. Statistical analysis
Data was analyzed by a computer with SPSS 11.0 software
(SPSS, Chicago, IL, U.S.A.) and p scores <0.05 were considered as
signiﬁcant. Categorical variables were compared by a Chi-square
test and Fisher’s exact test. For continuous variables, an unpaired t-
test was used for comparing two groups and ANOVA with
Bonferroni correction (two-tailed) for more than two groups. Risk
factors of the reproductive disorders were analyzed with Binary
logistic regression.
Table 2
Incidence and risk factor analysis of PCOS and its isolated components in Chinese WWE (n = 102).
AEDs Polycystic ovaries A/oligomenorrhoea Hyperandrogenism PCOS
 +  +  +  +
Number of cases (%) 73 (71.6) 29 (28.4) 82 (80.4) 20 (19.6) 95 (93.1) 7 (6.9) 89 (87.3) 13 (12.7)
Age of seizure start (mean  SD years) 17.2  8.6 14.0  4.9 16.7  8.5 14.6  7.1 16.6  8.4 11.0  3.4* 16.7  8.4 13.0  7.2*
Duration of seizure (mean  SD years) 6.3  5.9 5.7  4.6 6.1  5.8 6.3  4.5 6.0  5.6 8.1  3.7 6.0  5.6 .3  4.9
Type of seizure [n (%)]
SPS/CPS (n = 17) 11 (64.7) 6 (35.2) 15 (88.2) 2 (11.8) 16 (94.1) 1 (5.9) 16 (94.1) 1 (5.9)
PG/PSG (n = 60) 46 (76.7) 14 (23.3) 48 (80.0) 12 (20.0) 55 (91.7) 5 (8.3) 52 (86.7) 8 (13.3)
Unclassiﬁed (n = 25) 16 (64.0) 9 (36.0) 19 (76.0) 6 (24.0) 24 (96.0) 1 (4.0) 21 (84.0) 4 (16.0)
Frequency of seizure
Free in 3 months (n = 52) 36 (69.2) 16 (30.8) 40 (76.9) 12 (23.1) 46 (88.5) 6 (11.6) 49 (98.0) 1 (2.0)
Experience in 3 months (n = 50) 37 (74.0) 13 (26.0) 42 (84.0) 8 (16.0) 49 (98.0) 1 (2.0) 46 (92.0) 4 (8.0)
AEDs therapy [n (%)]
No therapy (n = 30) 25 (83.3) 5 (16.7) 27 (90.0) 3 (10.0) 30 (100) 0 (0.0) 30 (100) 0 (0.0)
AEDs therapy (n = 72) 48 (66.7) 24 (33.3)## 55 (76.4) 17 (23.6)## 65 (90.3) 7 (9.7)# 59 (81.9) 13 (18.1)##
Duration of AEDs therapy (mean  SD years) 2.5  3.1 3.7  3.7 2.6  3.2 3.6  3.6 2.6  3.2 5.0  3.9* 2.5  3.1 4.6  3.9*
* p < 0.05, vs. negative () patients, in an unpaired t-test.
# p < 0.05, vs. no AEDs therapy, in a Chi-square test.
## p < 0.01, vs. no AEDs therapy, in a Chi-square test.
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3.1. Clinical characteristics (Table 1)
The mean age of these 102 WWE was 22 years, ranging from 12-
to 45-year-old, and 88.2% patients were under 30-year-old. The
mean BMI was 21.9  3.6 kg/m2. The average ages of start of seizures
were 16.3  8.3 years old. The mean duration of disease was
6.2 years, ranging from 1 month to 29 years. Epileptic types included
simple or complex partial seizures (17 cases, 16.8%), primary
generalized seizures or secondary generalized from partial seizures
(60 cases, 58.8%), and unclassiﬁable seizures (25 cases, 24.5%).
Seventy-two patients (70.6%) received regular AED therapy, with 32
cases (44.4%) using valproic acid (VPA) either alone (21 cases) or
together with other AEDs (11 cases). The mean age at the start of AEC
therapy was 17.8  7.0 years and duration of the therapy
2.8  3.3 years. Four patients (3.9%) had hirsutism and/or acne, with
only 1 case of increased blood androgen levels.
3.2. Incidence of PCOS and its isolated components
There were 54.9% (56/102) patients with one or more of PCOS’s
components, including polycystic ovaries (29/102, 28.4%), a/
oligomenorrhoea (20/102, 19.6%), and hyperandrogenism (7/
102, 6.9%), and among them 13 cases (12.7%) were diagnosed as
PCOS. Several risk factors for these reproductive disorders were
further analyzed (Table 2). The mean age at the start of seizures
was 13.8  6.5 years in these patients with reproductive dysfunction,Table 3
Analysis of PCOS and its isolated components in 72 Chinese WWE used AEDs.
AEDs Polycystic ovaries A/Oligomenorrh
 +  
Signal AED [n (%)]
VPA (n = 21) 11 (52.4) 10 (47.6)* 13 (61.9) 
Another AED (n = 28a) 22 (78.6) 6 (21.4) 26 (92.9) 
2 AEDs [n (%)]
Non-VPA AEDs (n = 12) 10 (83.3) 2 (16.7) 10 (83.3) 
VPA + other AEDs (n = 11) 5 (45.5) 6 (54.5)* 6 (54.5) 
AEDs therapy [n (%)]
Non-VPA AEDs (n = 40) 32 (80.0) 8 (20.0) 36 (90.0) 
VPA (n = 32) 16 (50.0) 16 (50.0)# 19 (59.4) 
a Among them 13 patients used CBZ, 6 LTG, 5 TPM, and 4 OXC.
* p < 0.05, vs. non-VPA AEDs therapy, in a Chi-square test.
# p < 0.01, vs. non-VPA AEDs therapy, in a Chi-square test.with most cases under 16 years old. This is signiﬁcantly younger than
that of cases without the endocrine disorders (16.9  8.6 years,
p < 0.05). Although the length of time during which these patients
suffered seizures was relatively long (over 5 years in average), it is not
statistically different to that in cases without endocrine disorders.
There were also no statistical differences in the type or frequency of
epilepsy among patients with or without these reproductive
endocrine disorders. The occurrence of PCOS and its isolated
components, however, was associated with AEDs, particularly VPA
therapy (see below).
3.3. VPA therapy and PCOS
Among the 72 Chinese WWE who used AEDs (Table 3), patients
on VPA therapy, either alone or together with another AED, had
signiﬁcantly higher incidence of PCOS (11/32, 34.4%), a/oligome-
norrhea (13/32, 40.6%), polycystic ovaries (16/32, 50%), and
hyperandrogenism (5/32, 15.6%), in comparison to those without
therapy. A further analysis (Table 4), however, could not ascertain
whether or not the increased incidence of PCOS was associated to
the possible change of BMI during VPA therapy, or to other issues
including the dosage, duration, and the age at the start of use of
VPA therapy.
3.4. Circulating hormone levels
Circulating levels of sex hormones are presented in Table 5.
Serum level of testosterone was signiﬁcantly higher in patientsoea Hyperandrogenism PCOS
+  +  +
8 (38.1)* 17 (80.9) 4 (19.0) 13 (61.9) 8 (38.1)*
2 (7.1) 26 (92.9) 2 (7.1) 26 (92.9) 2 (7.1)
2 (16.7) 12 (100) 0 (0.0) 12 (100) 0 (0.0)
5 (45.5)* 10 (90.9) 1 (9.1) 8 (72.7) 3 (27.3)*
4 (10.0) 38 (95.0) 2 (5.0) 38 (95.0) 2 (5.0)
13 (40.6)# 27 (84.4) 5 (15.6)* 21 (65.5) 11 (34.4)#
Table 4
Analysis of risk factors of PCOS in 32 Chinese WWE used VPA therapy.
Factors With PCOS (n = 11) Without PCOS (n = 21) p value
BMI (mean  SD kg/m2) 23.6  5.47 20.9  3.61 NSa
<24 [n = 25, n (%)] 7 (28.0) 18 (72.0)
24 [n = 7, n (%)] 4 (57.1) 3 (42.9) NSb
Age at VPA start (mean  SD years) 15.7  6.0 16.0  7.5 NSa
18 [n = 20, n (%)] 9 (45.0) 11 (55.0)
>18 [n = 12, n (%)] 2 (16.7) 10 (83.8) NSb
Dose of VPA (mean  SD mg/day/kg) 14.7  6.85 13.9  5.78 NSa
15 [n = 19, n (%)] 6 (31.6) 13 (68.4)
>15 [n = 13, n (%)] 5 (38.5) 8 (61.5) NSb
Duration of therapy (mean  SD years) 5.03  1.80 4.89  1.85 NSa
<2 years [n = 13, n (%)] 4 (30.8) 9 (69.2)
2 years [n = 19, n (%)] 7 (36.8) 12 (63.2) NSb
a Not signiﬁcant (>0.05) in an unpaired t-test.
b Not signiﬁcant (>0.05) in a Chi-square test.
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the average level of the hormone did not reach to that of the
deﬁned hyperandrogenism. Serum LH level and LH/FSH ratio
were also signiﬁcantly higher in VPA-treated WWE (p < 0.05,
compared to those without the AED therapy). There were no
statistical changes in the levels of these hormones in patients
who accepted non-VPA AEDs compared to those without AED
therapy.
4. Discussion
Little information is available with regards to PCOS in Chinese
WWE. The present study, for the ﬁrst time, investigated the
incidence and risk factors of PCOS in Chinese WWE at
reproductive ages. The study found that 54.9% (56/102) cases
have at least one of the major isolated components of PCOS, such
as polycystic ovaries, hyperandrogenism, and a/oligomenorrhea.
The incidence rate of PCOS in these Chinese WWE was 12.7% (13/
102), around 2 to 3-folds of that in healthy women.1,2 This rate is
similar to that reported in Indian WWE (about 11.8%),12 but
lower than that in some reports in Western WWE (up to 26%).3
Incidence of PCOS in Chinese WWE was associated with seizure
start age and VPA therapy: patients who started suffering
seizures at ages 16 years or accepted VPA therapy were at
relatively higher risk of PCOS.
The causes and mechanisms underlying the occurrence of PCOS
in WWE are still not fully clear. Electrical discharges, both
interictally and during generalized and partial seizures, may alter
the secretion of pituitary and gonadal hormones,3,13,14 which may
result in reproductive dysfunction. Studies in western WWE1,3,6,7
have shown that reproductive endocrine and sexual dysfunction
are more common in patients with partial epilepsy than patients
with generalized epilepsy, particular that of temporal lobe origin.
In our study, however, no signiﬁcant difference in PCOS incidenceTable 5
Blood levels of hormones (mean  SD, n = 102).
No AEDs therapy (n = 30) 
T (ng/mL) 0.42  0.26 
LH (IU/L) 4.03  3.13 
FSH (IU/L) 5.03  1.80 
LH/FSH ratio 0.82  0.61 
DHEAS (mmol/l) 5.92  2.20 
PRL (ng/mL) 15.74  8.96 
E2 (pg/mL) 40.00  16.28 
P (ng/mL) 0.22  0.14 
a p < 0.01, vs. no AEDs therapy or other AED therapy.
b p = 0.023, vs. no AEDs therapy.
c p = 0.026, vs. no AEDs therapy.between partial and generalized epilepsy have been found in
Chinese WWE, which is similar to a recent report in Indian WWE.12
In fact, the relationship between seizure type and PCOS incidence
has not been found consistently in some western WWE. For
example, studies in Austrian and Italian WWE showed that
reproductive endocrine disorders occurred in similar frequency
irrespective of the type as well as frequency of seizures.15,16 These
studies, as well as the fact that high incidence of PCOS can also
occur in WWE with well-controlled seizures, implicate that the
seizure type and frequency are not prominent elements for PCOS.
Our study showed that the age at the start of seizures, but not the
type, duration and frequency of the disease, is related to PCOS, with
younger WWE (16 years old) having relatively higher incidence
of this disorder.
It is well known that AEDs, particularly VPA, may change
serum concentrations of reproductive hormones in patients with
epilepsy, thus contributing to the development of reproductive
dysfunction including PCOS.17–20 Therefore in this study we paid
particular attention to the incidence and risk factors of PCOS in
the Chinese WWE undergoing AEDs therapy. In agreement with
the studies by Isoja¨rvi et al.,8,16–21 our study found an increased
frequency of PCOS and its major isolated components in the
Chinese WWE undertaking VPA therapy, with the incident rate
of polycystic ovaries at 50.0%, a/oligomenorrhea 40.6%, hyper-
androgenism 15.6%, and PCOS 34.4%. However, we could not
clarify the relationship of the dose and duration of VPA therapy
to these reproductive endocrine disorders, possibly due to the
relatively small sample size in this study. A previous prospective
study in Indian WWE found an increased incidence of menstrual
disturbance and polycystic ovaries in the ﬁrst two years of VPA-
therapy in women.22 Similarly, in this study on Chinese WWE
about 1/3 (4 of 13) of cases of PCOS were diagnosed during the
ﬁrst 2 years of VPA therapy and longer VPA treatment (over
2 years) did not signiﬁcantly increase the incidence (Table 4). ToOther AEDs therapy (n = 40) VAP-therapy (n = 32)
0.47  0.28 0.74  0.37a
4.51  2.64 6.31  5.54b
4.89  1.85 4.95  1.23
1.03  0.73 1.27  0.97c
5.30  2.70 5.92  3.30
17.01  8.44 18.93  12.82
51.08  69.29 49.07  32.90
0.25  0.19 0.24  0.17
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reproductive dysfunction is still unknown. Although in our
study the incidence of PCOS in the WWE with non-VPA
AEDs was relatively lower than that in the VPA-treated patients
(Table 3), we could still not exclude the possible side effects of
these AEDs on reproductive function. This is because the sample
size for each non-VPA AED was too small to complete such
assessments.
Although increased PCOS in WWE using VPA therapy has been
reported in many studies, the underlying mechanisms and
pathogenesis are still not fully understood. As the use of VPA is
often associated with increased weight and hyperinsulinemia, it is
suggested that obesity and associated hyperinsulinemia contribute
to the development of polycystic ovaries and hyperandrogenism in
WWE who use VPA therapy.9,16,20 In this present study with 32
Chinese WWE with VPA therapy (Table 4), more than 1/3 (4 in 11)
of patients with PCOS have been found to be overweight
(IBM  24) whereas less than 1/5 (3 in 21) of those without PCOS
were. Although this difference did not reach statistical signiﬁcance
due to a small sample size in this study, the result still supports
that obesity is associated with the occurrence of PCOS in WWE who
use VPA therapy. VPA therapy may affect sex hormone production.
Studies in vitro demonstrated that VPA directly stimulated ovarian
production of androgens, leading to increased circulating levels of
these sex hormones and thus reproductive disorders including
PCOS.23 Our study showed that circulating levels of testosterone
were signiﬁcantly elevated in the Chinese WWE with VPA therapy
(Table 5). In this study blood LH levels and LH/FSH ratio in the
patients with VPA therapy were also found to be higher than those
without the AED therapy, but we could not conﬁrm that
the increased LH was an initial issue caused by VPA treatment
or a secondary issue (feedback phenomenon) following PCOS.
Although high serum LH levels may also increase ovarian synthesis
of androgens, previous studies found that VPA was not associated
with elevated serum LH levels.16,17 Therefore, the role of high LH in
VPA-induced PCOS remains uncertain.
5. Limitations of the study
The major limitation of our study was a small sample size,
particularly small numbers of WWE in antiepileptic subgroups.
6. Conclusion
The study demonstrates that PCOS occurs in 12.7% of Chinese
WWE at reproductive ages, by more than 2 times of that in a
healthy population. The incidence of PCOS as well as its isolated
components is associated with the age at the start of seizures, with
higher frequency of these reproductive endocrine disorders
occurring in those who had younger ages of seizure onset
(16 years old). VPA therapy is another important risk factor
associated with PCOS in Chinese WWE. At this time, the
underlying mechanisms remain unclear. Larger prospective
studies which would provide the information about relationships
between the dose and duration of VPA therapy as well as the use of
other AEDs to the onset of PCOS symptoms in Chinese WWE are
required.
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